

752. Table 4 suggests that the difference of the two methods is not ignorable, on average, judging by statistical significance when $F \geq 0.4$, because the CI by the generalized method included 1.0, whereas CI by the usual method did not.

The essential feature of the influence of the generalized method on the judgment of association can be seen in Table 5, which is the mean of R_p , R_s , N_{TP} , and N_{FP} obtained from the 1,000 simulation repetitions. When $\psi=1.5$ or 2.0, $w=0.02, 0.06$ or 0.10 and $\mu=0.2$ or 0.4, the false positive number of SNPs in the generalized method was, on average, slightly less than that in the usual method.

Discussion

The essential improvement achieved by the generalized method is summarized in Table 5. In this table, for example, the average number of falsely detected SNPs by the usual method was 22.0 ($n=188$) or 22.0 ($n=752$), whereas it was 20.4 ($n=188$) or 19.7 ($n=752$) by the generalized method when $\psi=2.0, w=0.10$ and $\mu=0.4$. The amount of the improvement was not great, but it may be appreciated in certain research circumstances, because a difference of even a few SNPs would be highly significant in the advanced stages of gene hunting following an association study, such as large-scale, multiethnic replication studies or lengthy functional analyses on model animals. It should be noted that a substantial investment in the post-association study is often necessary, especially in a hypothesis-free genome scan, in which a prior probability of the gene is minimal.

Deviation from HWE is not a rare, exceptional case in association studies. Figure 2 shows an example of the distribution of the fixation index in a large-scale SNP typing project, in which 84,542 SNP typing data on autosomal chromosomes were obtained for 940

individuals in the Millennium Genome Project of Japan (Haga et al. 2002; Yoshida and Yoshimura 2003). In this dataset, the operating protocol of our SNP typing laboratory includes routine quality check steps to filter simple experimental errors. However, even after the careful check for the genotyping errors, a sizable fraction of about 2% of the 84,542 SNPs showed a fixation index outside the normal range of variation under the hypothesis that the population fixation index was 0.

As for other data, Wittke-Thompson et al. (2005) did a survey of HWD in several recent reviews of association studies (Xu et al. 2002; Gyorffy et al. 2004; Kocsis et al. 2004a, b; Osawa et al. 2004) and identified 41 studies with 60 polymorphisms showing a departure from HWE: 35 polymorphisms that depart from HWE in cases only, 21 that departed in controls only, 2 that departed in the same direction in cases and controls, and 1 that departed in the opposite direction in cases and controls. Wittke-Thompson et al. (2005) emphasized the importance not only of correctly assessing HWE for genotype data but also of understanding whether an observed HWD was consistent with a genetic model of disease susceptibility.

In a previous study, Schaid and Jacobsen (1999), Zaykin et al. (2004) and Salanti et al. (2005) each recommended the correction of the variance of the observed statistics which is allele frequency difference, relative risk or odds ratio under HWD, respectively, because the type I error for gene-disease associations tested on the level of alleles was inflated when the estimated inbreeding coefficient was positive, while the error deflates for the negative coefficient. However, under circumstances where the assumptions of HWE in controls and codominance between the alleles do not hold well, Sasieni (1997) recommended simply to abandon the allelic odds ratio for an association study, because the allelic odds ratio and chi-square statistics are not robust under such circumstances. These previ-

Table 4 Difference of confidence interval between two methods for various fixation indices $F=F_1=F_2$ at $P_{11}=0.15$ and $P_{12}=0.10$

Fixation index F	$n=n_1=n_2=188$				$n=n_1=n_2=752$			
	Usual method		Generalized method		Usual method		Generalized method	
	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
- 0.10	1.047	2.551	1.071	2.494	1.282	1.994	1.298	1.972
0.00	1.048	2.556	1.049	2.554	1.283	1.995	1.283	1.995
0.20	1.054	2.577	1.012	2.684	1.284	1.997	1.258	2.039
0.40	1.059	2.594	0.978	2.809	1.286	2.001	1.236	2.083
0.60	1.066	2.620	0.949	2.946	1.289	2.006	1.216	2.126

The range of fixation index (F_j) depends on the population probabilities allele X and is shown by the following equation:

$$-\frac{p_{1j}}{1-p_{1j}} \leq F_j \leq 1 (j = 1, 2)$$

Table 5 Observed means of positive predicative value (R_p), sensitivity (R_s), true positive SNPs (N_{TP}), and false positive SNPs (N_{FP}) obtained in the simulation experiment ($F_1>0$ and $F_2=0$)

ψ	w	μ	Method	$n=188$		$n=376$		$n=752$	
				Usual	General	Usual	General	Usual	General
1.5	0.02	0.2	R_p	0.502	0.503	0.641	0.645	0.695	0.701
			R_s	0.411	0.412	0.727	0.724	0.924	0.921
			N_{TP}	20.6	20.6	36.3	36.2	46.2	46.0
		0.4	N_{FP}	20.4	20.3	20.4	19.9	20.3	19.6
			R_p	0.496	0.500	0.640	0.646	0.646	0.701
			R_s	0.410	0.411	0.728	0.725	0.924	0.922
	0.06	0.2	N_{TP}	20.5	20.6	36.4	36.3	36.2	46.1
			N_{FP}	20.8	20.6	20.5	19.8	19.8	19.7
			R_p	0.499	0.504	0.636	0.645	0.689	0.700
		0.4	R_s	0.414	0.415	0.730	0.725	0.923	0.919
			N_{TP}	20.7	20.7	36.5	36.3	46.1	46.0
			N_{FP}	20.8	20.4	20.9	20.0	20.8	19.7
	0.10	0.2	R_p	0.492	0.501	0.629	0.640	0.687	0.703
			R_s	0.414	0.412	0.725	0.720	0.922	0.919
			N_{TP}	20.7	20.6	36.2	36.0	46.1	45.9
		0.4	N_{FP}	21.3	20.5	21.4	20.2	21.0	19.4
			R_p	0.490	0.498	0.636	0.647	0.688	0.702
			R_s	0.410	0.410	0.731	0.727	0.924	0.920
	2.0	0.02	N_{TP}	20.5	20.5	36.6	36.4	46.2	46.0
			N_{FP}	21.3	20.6	20.9	19.8	20.9	19.5
			R_p	0.483	0.499	0.626	0.646	0.679	0.700
		0.06	R_s	0.410	0.408	0.725	0.720	0.923	0.919
			N_{TP}	20.5	20.4	36.3	36.0	46.2	45.9
			N_{FP}	21.9	20.5	21.7	19.7	21.8	19.7
0.10	0.2	R_p	0.677	0.675	0.702	0.706	0.707	0.715	
		R_s	0.849	0.845	0.961	0.958	0.992	0.991	
		N_{TP}	42.4	42.2	48.1	47.9	49.6	49.6	
	0.4	N_{FP}	20.2	20.3	20.4	19.9	20.5	19.8	
		R_p	0.672	0.673	0.697	0.704	0.706	0.715	
		R_s	0.850	0.846	0.959	0.956	0.992	0.991	
0.06	0.2	N_{TP}	42.5	42.3	48.0	47.8	49.6	49.6	
		N_{FP}	20.8	20.5	20.8	20.1	20.7	19.7	
		R_p	0.672	0.675	0.700	0.708	0.704	0.716	
	0.4	R_s	0.849	0.845	0.962	0.959	0.992	0.991	
		N_{TP}	42.4	42.2	48.1	47.9	49.6	49.6	
		N_{FP}	20.8	20.3	20.7	19.8	20.9	19.7	
0.10	0.2	R_p	0.666	0.674	0.694	0.707	0.704	0.719	
		R_s	0.849	0.844	0.961	0.958	0.992	0.991	
		N_{TP}	42.5	42.2	48.0	47.9	49.6	49.6	
	0.4	N_{FP}	21.3	20.4	21.2	19.8	20.9	19.3	
		R_p	0.670	0.676	0.697	0.708	0.702	0.716	
		R_s	0.851	0.847	0.960	0.957	0.992	0.992	
0.06	0.2	N_{TP}	42.6	42.3	48.0	47.9	49.6	49.6	
		N_{FP}	20.9	20.2	20.9	19.8	21.1	19.7	
		R_p	0.657	0.673	0.687	0.706	0.693	0.716	
	0.4	R_s	0.846	0.839	0.963	0.960	0.992	0.991	
		N_{TP}	42.3	42.0	48.1	48.0	49.6	49.5	
		N_{FP}	22.0	20.4	22.0	20.0	22.0	19.7	

The fixation index (F) in a case group was specified by a mixed distribution of a constant 0 with probability $1-w$ and a normal distribution $N(\mu, 0.10^2)$ with probability w , where $w=0.02, 0.06$ or 0.10 , and μ was set as $0.2, \text{ or } 0.4$. In a control group F was set to 0

ous studies were targeted at a candidate-gene association study or meta-analysis and did not examine a genome-wide association study. Here, we scrutinized the situation in a genome-wide association study and showed that around 2% of the large tail area was laid

outside the distribution of F , suggesting the importance of the correction under HWD. Because the cardinal feature of the genome-wide association study is a screening, we believe that Sasieni's recommendation may be too conservative to be accepted, and the

generalized method should be applied as a sensitivity analysis in a genome-wide association study to improve both false positive rate (for $F>0$) and false negative rate (for $F<0$).

Acknowledgments We thank Professor Toshiya Sato at Kyoto University and Dr. Takashi Sozu at Tokyo University of Science for their valuable advice in improving this paper. We are grateful to the anonymous reviewers for their useful comments, which greatly improved this paper. This study was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan.

Appendix: Mathematical details

Let the population probabilities of genotypes “ XX ”, “ Xx ”, and “ xx ” be π_1 , π_2 and π_3 ($\pi_1 + \pi_2 + \pi_3=1$), respectively, then those of alleles “ X ” and “ x ” for a SNP are given by Eq. 10.

$$P_1 = \pi_1 + \pi_2/2, \quad P_2 = \pi_3 + \pi_2/2 (= 1 - P_1). \quad (10)$$

When we use the fixation index (Li et al. 1953) defined by

$$F = 1 - \frac{\pi_2}{2(\pi_1 + \pi_2/2)(\pi_3 + \pi_2/2)}, \quad (11)$$

(π_i ; $i=1, 2, 3$) are expressed as Eq. 12.

$$\left. \begin{aligned} \pi_1 &= P_1^2 + FP_1P_2 \\ \pi_2 &= 2P_1P_2 - 2FP_1P_2 \\ \pi_3 &= P_2^2 + FP_1P_2 \end{aligned} \right\} \quad (12)$$

Therefore, (π_1, π_2, π_3) is equivalent to (P_1, P_2, F).

When the Hardy–Weinberg equilibrium (HWE) holds, $F=0$ and Eq. 12 reduces to Eq. 13; that is, the second term in the right side of Eq. 12 represents the degree of disequilibrium.

$$\pi_1 = P_1^2, \quad \pi_2 = 2P_1P_2, \quad \pi_3 = P_2^2. \quad (13)$$

For a random sample of size n , the observed frequency (n_1, n_2, n_3); ($n_1 + n_2 + n_3=n$) of genotypes (XX, Xx, xx) is distributed as trinomial distribution $Tn(n; \pi_1, \pi_2, \pi_3)$ and, therefore, the maximum likelihood estimator of π_i ($i=1, 2, 3$) is $p_i=n_i/n$ ($i=1, 2, 3$). Likewise, the maximum likelihood estimators of P_1 and allele odds $P_1/(1 - P_1)$ are $\hat{P}_1 = p_1 + p_2/2 = (2n_1 + n_2)/(2n)$, and $\hat{P}_1/(1 - \hat{P}_1)$, respectively.

Since the means, variances, and covariance of p_1 and p_2 are given (Bishop et al. 1975; Agresti 2001) by

$$\left. \begin{aligned} E\{p_1\} &= \pi_1 = P_1^2 + FP_1P_2 \\ E\{p_2\} &= \pi_2 = 2P_1P_2 - 2FP_1P_2 \\ V\{p_1\} &= \frac{1}{n}\pi_1(1 - \pi_1) = \frac{1}{n}(P_1^2 + FP_1P_2)(1 - P_1^2 - FP_1P_2) \\ V\{p_2\} &= \frac{1}{n}\pi_2(1 - \pi_2) = \frac{1}{n}(2P_1P_2 - 2FP_1P_2) \\ &\quad \times (1 - 2P_1P_2 + 2FP_1P_2) \\ \text{Cov}\{p_1, p_2\} &= -\frac{1}{n}\pi_1\pi_2 = -\frac{1}{n}(P_1^2 + FP_1P_2) \\ &\quad \times (2P_1P_2 - 2FP_1P_2) \end{aligned} \right\} \quad (14)$$

the mean and variance of \hat{P}_1 is, after a simple but tedious algebra, derived as Eqs. 15 and 16.

$$\begin{aligned} E\{\hat{P}_1\} &= E\{p_1\} + \frac{1}{2}E\{p_2\} \\ &= P_1^2 + FP_1P_2 + \frac{1}{2}2(P_1P_2 - FP_1P_2) \\ &= P_1(P_1 + P_2) = P_1, \end{aligned} \quad (15)$$

$$\begin{aligned} V\{\hat{P}_1\} &= V\{p_1\} + 2\frac{1}{2}\text{Cov}\{p_1, p_2\} + \left(\frac{1}{2}\right)^2 V\{p_2\} \\ &= \frac{1}{n}(P_1^2 + FP_1P_2)(1 - P_1^2 - FP_1P_2) \\ &\quad - \frac{1}{n}(P_1^2 + FP_1P_2)(2P_1P_2 - 2FP_1P_2) \\ &\quad + \frac{1}{4n}(2P_1P_2 - 2FP_1P_2)(1 - 2P_1P_2 + 2FP_1P_2) \\ &= \frac{P_1P_2}{2n}(2F(P_1 + P_2)^2 + 1 - F) \\ &= \frac{P_1(1 - P_1)}{2n}(1 + F). \end{aligned} \quad (16)$$

When $F=0$, the last term is the well-known formula for binomial proportion for the size $2n$ and probability P_1 . It reflects that the distribution of the frequency of allele X under HWE is the same as that of allele X randomly chosen from $2n$ alleles with P_1 as the proportion of X .

Since \hat{P}_1 tends to P_1 in probability when n tends to infinity, the logarithm of estimated allelic odds, $\log(\hat{P}_1/(1 - \hat{P}_1))$, can be approximated by the first order Taylor expansion as Eq. 17.

$$\log\left(\frac{\hat{P}_1}{1 - \hat{P}_1}\right) \approx \log\left(\frac{P_1}{1 - P_1}\right) + \frac{1}{P_1(1 - P_1)}(\hat{P}_1 - P_1). \quad (17)$$

Consequently, the mean and variance of $\log(\hat{P}_1/(1 - \hat{P}_1))$ are asymptotically approximated by Eqs. 18 and 19:

$$E\left\{\log\left(\frac{\hat{P}_1}{1-\hat{P}_1}\right)\right\} \approx \log\left(\frac{P_1}{1-P_1}\right), \tag{18}$$

$$\begin{aligned} V\left\{\log\left(\frac{\hat{P}_1}{1-\hat{P}_1}\right)\right\} &\approx \frac{1}{P_1^2(1-P_1)^2} V\{\hat{P}_1\} \\ &= \frac{1}{2nP_1(1-P_1)} (1+F) \\ &= \left(\frac{1}{2nP_1} + \frac{1}{2n(1-P_1)}\right) (1+F). \end{aligned} \tag{19}$$

When we consider the populations of cases and controls of a disease, the association between allele and disease is conventionally represented by the allele odds ratio ψ defined by Eq. 20, where the case and the control are differentiated with the second subscript 1 (case) and 2 (control).

$$\psi = \frac{P_{11}}{1-P_{11}} / \frac{P_{12}}{1-P_{12}}. \tag{20}$$

Consider we have random samples of size $n_{.1}$ and $n_{.2}$ from cases and controls, respectively. Then the maximum likelihood estimator $\hat{\psi}$ of ψ is given by Eq. 21, where \hat{P}_{11} and \hat{P}_{12} are the maximum likelihood estimators based on samples of case and control, respectively.

$$\hat{\psi} = \frac{\hat{P}_{11}}{1-\hat{P}_{11}} / \frac{\hat{P}_{12}}{1-\hat{P}_{12}}. \tag{21}$$

Since the sample of case and that of control can be assumed independent, we obtain Eqs. 22 and 23.

$$\begin{aligned} E\{\log \hat{\psi}\} &= E\left\{\log\left(\frac{\hat{P}_{11}}{1-\hat{P}_{11}}\right)\right\} - E\left\{\log\left(\frac{\hat{P}_{12}}{1-\hat{P}_{12}}\right)\right\} \\ &\approx \log\left(\frac{P_{11}}{1-P_{11}}\right) - \log\left(\frac{P_{12}}{1-P_{12}}\right) = \log(\psi), \end{aligned} \tag{22}$$

$$\begin{aligned} V\{\log \hat{\psi}\} &= V\left\{\log\left(\frac{\hat{P}_{11}}{1-\hat{P}_{11}}\right)\right\} + V\left\{\log\left(\frac{\hat{P}_{12}}{1-\hat{P}_{12}}\right)\right\} \\ &\approx \left(\frac{1}{2n_{.1}P_{11}} + \frac{1}{2n_{.1}(1-P_{11})}\right) (1+F_1) \\ &\quad + \left(\frac{1}{2n_{.2}P_{12}} + \frac{1}{2n_{.2}(1-P_{12})}\right) (1+F_2), \end{aligned} \tag{23}$$

where F_1 and F_2 are fixation indices of case and control, respectively.

When we construct an asymptotic confidence interval of $\log(\psi)$ with confidence level $1-\alpha$, we should replace $V\{\log(\hat{\psi})\}$ with its estimator given by Eq. 24.

$$\begin{aligned} \hat{V}\{\log \hat{\psi}\} &= \left(\frac{1}{2n_{11} + n_{21}} + \frac{1}{2n_{31} + n_{21}}\right) (1 + \hat{F}_1) \\ &\quad + \left(\frac{1}{2n_{12} + n_{22}} + \frac{1}{2n_{32} + n_{22}}\right) (1 + \hat{F}_2), \end{aligned} \tag{24}$$

where \hat{F}_1, \hat{F}_2 are as follows:

$$\hat{F}_j = 1 - \frac{2n_{2j}n_{.j}}{(2n_{1j} + n_{2j})(2n_{3j} + n_{2j})} \quad j = 1, 2. \tag{25}$$

References

Agresti A (2001) *Categorical data analysis*, 2nd edn. Wiley, New York

Balding D, Bishop M, Cannings C (2001) *Handbook of statistical genetics*. Wiley, New York

Bishop Y, Fienberg S, Holland P (1975) *Discrete multivariate analysis: theory and practice*. MIT Press, Cambridge

Gyorffy B, Kocsis I, Vasahelyi B (2004) Biallelic genotype distributions in papers published in Gut between 1998 and 2003: altered conclusions after recalculating the Hardy-Weinberg equilibrium. *Gut* 53:614-616

Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T (2002) Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. *Single-nucleotide polymorphism. J Hum Genet* 47:605-610

Hirakawa M, Tanaka T, Hashimoto Y, Kuroda M, Takagi T, Nakamura Y (2002) JSNP: a database of common gene variations in the Japanese population. *Nucleic Acids Res* 30:158-162

Hirschhorn JN, Daly MJ (2005) Genome-wide association studies for common diseases and complex traits. *Nat Rev Genet* 6:95-108

International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of the human genome. *Nature* 431:931-945

Kocsis I, Gyorffy B, Nemeth E, Vasahelyi B (2004a) Examination of Hardy-Weinberg equilibrium in papers of *Kidney International*: an underused tool. *Kidney Int* 65:1956-1958

Kocsis I, Vasahelyi B, Gyorffy A, Gyorffy B (2004b) Reanalysis of genotype distributions published in *Neurology* between 1999 and 2002. *Neurology* 63:357-358

Li CC, Horvitz DG (1953) Some methods of estimating the inbreeding coefficient. *Am J Hum Genet* 5:107-117

Nei M (1987) *Molecular evolutionary genetics*. Columbia University Press, New York

Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiyama T, Niya T, Shimizu I, Nishida W, Hashiramoto M, Kanatsuka A, Fujii Y, Ohashi J, Makino H (2004) The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. *Am J Hum Genet* 75:678-686

- Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (2002) Polygenic susceptibility to breast cancer and implications for prevention. *Nat Genet* 31:33–36
- Ponder BA (2001) Cancer genetics. *Nature* 17:336–341
- Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S et al (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. *Nature* 409:928–933
- Salanti G, Amountza G, Ntzani EE, Ioannidis JP (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. *Eur J Hum Genet* 13:840–848
- Sasieni PD (1997) From genotypes to genes: doubling the sample size. *Biometrics* 53:1253–1261
- Sato Y, Suganami H, Hamada C, Yoshimura I, Yoshida T, Yoshimura K (2004) Designing a multistage, SNP-based, genome screen for common diseases. *J Hum Genet* 49:669–676
- Schaid DJ, Jacobsen SJ (1999) Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. *Am J Epidemiol* 149:706–711
- Sing F, Haviland B, Reilly L (1996) Genetic architecture of common multifactorial diseases. In: *Variation in the Human Genome* (Ciba Foundation Symposium 1997). Wiley, Chichester, pp 211–229
- Wittke-Thompson JK, Pluzhnikov A, Cox NJ (2005) Rational Inferences about Departures from Hardy-Weinberg Equilibrium. *Am J Hum Genet* 76:967–986
- Wright S (1951) The genetical structure of populations. *Ann Eugen* 15:23–354
- Wright S (1965) The interpretation of population structure by F-statistics with special regard to systems of mating. *Evolution* 19:395–420
- Wright AF, Carothers AD, Pirastu M (1999) Population choice in mapping genes for complex diseases. *Nat Genet* 23:397–404
- Xu J, Turner A, Little J, Bleecker ER, Meyers DA (2002) Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? *Hum Genet* 111:573–574
- Yoshida T, Yoshimura K (2003) Outline of disease gene hunting approaches in the Millennium Genome Project of Japan. *Proc Jpn Acad Ser B* 79:34–50
- Zaykin DV, Meng Z, Ghosh SK (2004) Interval estimation of genetic susceptibility for retrospective case-control studies. *BMC Genet* 5:9

Meeting Report

Mouse Lymphoma Thymidine Kinase Gene Mutation Assay: Follow-up Meeting of the International Workshop on Genotoxicity Testing—Aberdeen, Scotland, 2003—Assay Acceptance Criteria, Positive Controls, and Data Evaluation

Martha M. Moore,^{1*} Masamitsu Honma,² Julie Clements,³ George Bolcsfoldi,⁴ Brian Burlinson,⁵ Maria Cifone,⁶ Jane Clarke,⁷ Robert Delongchamp,¹ Robert Durward,⁸ Michael Fellows,⁹ Bhaskar Gollapudi,¹⁰ Saimei Hou,⁴ Peter Jenkinson,⁸ Melvin Lloyd,³ Jenness Majeska,¹¹ Brian Myhr,⁶ Michael O'Donovan,⁹ Takashi Omori,¹² Colin Riach,¹³ Richard San,⁷ Leon F. Stankowski Jr.,¹⁴ Ajit K. Thakur,⁶ Freddy Van Goethem,¹⁵ Shinobu Wakuri,¹⁶ and Isao Yoshimura¹⁷

¹National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas

²National Institute of Health Sciences, Division of Genetics and Mutagenesis, Tokyo, Japan

³Covance Laboratories, Ltd., Harrogate, North Yorkshire, United Kingdom

⁴Safety Assessment, AstraZeneca R&D, Sodertalje, Sweden

⁵Huntingdon Life Sciences, Huntingdon, United Kingdom

⁶Covance Laboratories Inc., Vienna, Virginia

⁷BioReliance Invitrogen Bioservices, Rockville, Maryland

⁸Safepharma Laboratories Ltd., Shardlow, Derbyshire, United Kingdom

⁹Safety Assessment, AstraZeneca R&D, Alderley Park, Macclesfield, United Kingdom

¹⁰The Dow Chemical Company, TERC, Midland, Michigan

¹¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut

¹²Kyoto University School of Public Health, Kyoto, Japan

¹³Inveresk (A Charles River Company), Tranent, Scotland

¹⁴Johnson & Johnson Pharmaceutical Research and Development L.L.C., Raritan, New Jersey

¹⁵Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium

¹⁶Hatano Research Institute, Food and Drug Safety Center, Kanagawa, Japan

¹⁷Faculty of Engineering, Tokyo University of Science, Shinjuku-ku, Tokyo, Japan

The Mouse Lymphoma Assay (MLA) Workgroup of the International Workshop on Genotoxicity Testing (IWGT), comprised of experts from Japan, Europe, and the United States, met on August 29, 2003, in Aberdeen, Scotland, United Kingdom. This meeting of the MLA Workgroup was devoted to reaching a consensus on the appropriate approach to data eval-

uation and on acceptance criteria for both the positive and negative/vehicle controls. The Workgroup reached consensus on the acceptance criteria for both the agar and microwell versions of the MLA. Recommendations include acceptable ranges for mutant frequency, cloning efficiency, and suspension growth of the negative/vehicle controls and on criteria to define

*Correspondence to: Martha M. Moore, NCTR/DGRT, HFT-120, 3900 NCTR Road, Jefferson, AR 72079, USA.
E-mail: MMMoore@nctr.fda.gov

Received 1 April 2005; provisionally accepted 14 April 2005; and in final form 13 May 2005

DOI 10.1002/em.20159

Published online 30 June 2005 in Wiley InterScience (www.interscience.wiley.com).

on acceptable positive control response. The recommendation for the determination of a positive/negative test chemical response includes both the requirement that the response exceeds a defined value [the

global evaluation factor (GEF)] and that there also be a positive dose-response (evaluated by an appropriate statistical method). *Environ. Mol. Mutagen.* 47:1-5, 2006. Published 2005 Wiley-Liss, Inc.¹

Key words: mouse lymphoma assay; thymidine kinase; gene mutation assay

INTRODUCTION

The Mouse Lymphoma Assay (MLA) Workgroup of the International Workshop on Genotoxicity Testing (IWGT), comprised of experts from Japan, Europe, and the United States, met on August 29, 2003, in Aberdeen, Scotland, United Kingdom. This meeting of the MLA Workgroup was devoted to reaching a consensus on the appropriate approach to data evaluation and on acceptance criteria for the positive controls. In addition, on the basis of new data, the group slightly revised the acceptance criteria for the negative controls that had been agreed upon at the last group meeting, held on June 28 and 29, 2002 in Plymouth, England, United Kingdom [Moore et al., 2003].

Since its first meeting, held as a part of the IWGT Procedures in Washington, DC, in the spring of 1999, the MLA Workgroup has been endeavoring to address three main issues of importance to the assay. These include (1) the conduct of a data-based analysis upon which to base a final recommendation for measuring cytotoxicity; (2) the criteria for data acceptance and appropriate approaches for data evaluation; and (3) the issues related to the International Committee for Harmonization (ICH) recommended use of a 24-hr treatment time (including the ability of the assay to detect aneugens). This is the 4th meeting of the Workgroup in which consensus has been reached and reported. The previous three meetings are reported in Moore et al. [2000, 2002, 2003].

ACCEPTANCE CRITERIA FOR NEGATIVE/VEHICLE CONTROLS

During the June 2002 meeting of the Workgroup in Plymouth, acceptance criteria were agreed upon for the MLA [Moore et al., 2003]. Following the meeting, the various laboratories revisited their methods for scoring mutant colonies. One laboratory conducting the microwell version of the assay and counting stained colonies determined that many of the colonies previously scored were below the size normally considered by others to be scoreable mutants. Additional experiments using unstained wells resulted in an overall lowering of the background mutant frequencies (MFs) from that laboratory and in a modification of the overall multiple laboratory distribution. The new global distribution for the negative/vehicle control MFs for the microwell version of the assay is shown in Figure 1. Based on this new information, the

majority of the Workgroup members agreed that the acceptable ranges for the negative/vehicle control MF for the microwell version of the assay should be revised to $(50-170) \times 10^{-6}$.

For both methods, the cloning efficiency (CE) referred to in the criteria is the absolute CE obtained at the time of mutant selection. The suspension growth (SG) of the negative/vehicle control refers to the growth during the 2-day expression period following 3- or 4-hr treatments. It is defined as the fold-increase of the cell number during this 2-day period. The SG is calculated by the day 1 fold-increase in cell number multiplied by the day 2 fold-increase in cell number.

The acceptance criteria for all of the negative/vehicle control parameters for the soft agar and microwell methods of performing the MLA are now as follows:

	Agar method	Microwell method
MF	$(35-140) \times 10^{-6}$	$(50-170) \times 10^{-6}$
CE	(65-120)%	(65-120)%
SG	8-32	8-32

ACCEPTANCE CRITERIA FOR POSITIVE CONTROLS

Positive control cultures should be included in every MLA experiment. This is done to assure that the assay is working within historical experience and that both the large and small-colony thymidine kinase (*Tk*) mutants are being adequately enumerated in each experiment. Because of the importance of adequate small colony mutant recovery, the Workgroup has chosen to develop criteria for the positive control that includes an appropriate increase in the small-colony *Tk* MF.

During the meeting in Plymouth, the Workgroup agreed to investigate a single reference chemical treatment that would be used for the MLA without S9 activation, and a single reference chemical treatment that would be used with S9 activation [Moore et al., 2003]. Following the meeting, it became apparent that achieving this goal required more effort than anticipated. Therefore, the Workgroup developed a different strategy for this requirement to provide assurance that adequate small and large colony mutant recovery was attained in an individual experiment.

The majority of the Workgroup members agreed upon two different approaches to assuring an adequate positive control response. Either approach is acceptable. In the




Fig. 1. Distribution plots of the negative/vehicle control MFs were as follows: (A) six laboratories conducting the microwell version and (B) four laboratories conducting the agar version of the MLA assay. The number of experimental observations is plotted in histogram form for incremental increases in mutant frequency ($\times 10^{-6}$). Units of 10 were used for the increments with the exception of the agar data where increments of 15 or 5 are used for the 20-35 and 35-40 increases, respectively. The GEF, calculated as the mean of the distribution plus one standard deviation, is indicated for each version of the MLA.

first approach, the laboratory should use a dose of a chemical that yields an absolute increase in total MF, that is an increase above the spontaneous background MF [an induced MF (IMF)] of at least 300×10^{-6} . At least 40% of the IMF should be reflected in the small colony MF. For instance, in a culture showing an IMF of 300×10^{-6} , the small colony IMF should be at least 120×10^{-6} . The second approach requires the use of a dose of a chemical that increases the small colony MF at least 150×10^{-6} above that seen in the concurrent negative/vehicle control (a small colony IMF of 150×10^{-6}).

Furthermore, the upper limit of cytotoxicity observed in the positive control culture should be the same as for the experimental cultures. That is, the relative total growth (RTG) should be greater than 10% [Moore et al., 2002]. While some laboratories prefer to use more than one dose of their positive control, it is sufficient to use a single dose (or one of the doses of the positive control cultures if more than one dose is used) to demonstrate that the acceptance criteria for the positive control have been satisfied.

DATA EVALUATION

Proper assay evaluation includes assuring that the negative/vehicle controls are acceptable and that the appropriate test chemical dose range has been obtained. For more detail on the Workgroup recommendations on the steps for proper assay evaluation, the reader is referred to the summaries of the New Orleans and Plymouth meetings [Moore et al., 2002, 2003]. Once the criteria for experimental acceptance have been satisfied, the data from each individual experiment can be evaluated to determine whether the response is positive, negative, or equivocal.

The Workgroup agreed that none of the previously used methods to evaluate MLA data is entirely satisfactory. With the goal of recommending one or more statistical methods, the group utilized actual experimental data collected from 10 laboratories (six microwell labs and four agar labs) and applied 29 statistical methods to these 398 data sets. A brief summary of this analysis and a complete list of the statistical methods are included in the Plymouth Meeting Report [Moore et al., 2003]. A complete description of this analysis will be written. The statistical methods used can be defined by the dependent variable (MF, log MF, or rank MF) and the independent variable(s) (dose, dose categories, dose + dose \times dose, log dose, or rank dose) and the weight [none, variance (dependent variable)].

There were several conclusions from the analyses of the statistical methods. When $P < 0.05$ was used to define a data set as positive, all of the statistical methods agreed on the positive or negative call in approximately 40% of the data sets. However, for approximately 60% of the data sets, the various statistical methods gave divergent positive/negative results. Based on this analysis, it was impossible to select one or more statistical methods that the Workgroup could confidently recommend to determine whether a chemical was positive or negative in the MLA. That is, for a large portion of the evaluated data sets, statistical methods could be selected that would result in either a positive or negative call.

It should be noted that a large percentage of the database was composed of chemicals that gave only small increases in MF. That is, the data were representative of that generally seen in laboratories testing chemicals of unknown mutagenicity. It is easy to classify chemicals that induce large increases in MF as positive. The difficulty arises in those situations where the increase in MF is very small. Statistical methods are designed to estimate the probability that a particular response occurred by chance. Therefore, those experiments having little variability between duplicate cultures or data points fitting tightly to a linear (or quadratic) curve are more likely to be judged positive (by statistical analysis) than experiments showing large variability. It is clear that the actual variability for any dose of a test chemical is not

adequately represented in any single experiment. In fact, from our analysis, the response distribution is not well defined until approximately 50 experiments are included [Moore et al., 2003]. Therefore, a positive or negative call should not be based solely upon the variability observed within an individual experiment.

It should also be noted that the data evaluation issues mentioned earlier are not unique to the MLA. Other genetic toxicology assays have similar issues in regard to data evaluation and data interpretation.

The background MF for the MLA shows a broad range of values (Fig. 1). It is clear that all laboratories generate some experiments where a "statistically" positive dose-response curve can fit within the normal range of the background MF.

Based on these considerations and taking into account previous guidance documents (i.e., FDA Redbook [<http://www.cfsan.fda.gov/~redbook/red-toca.html>] and OECD [1997]), which state that biological relevance should be a major factor in data evaluation, the majority of the members of the Workgroup decided to take a different approach to data analysis.

The majority of the Workgroup members agreed that a biologically relevant approach to MLA data evaluation might be achieved by requiring that the IMF exceed some value based on the global background MF for each method (agar or microwell). The basic concept for this approach was discussed at the meeting in Plymouth and a complete discussion of the rationale for this approach can be found in Moore et al. [2003]. This value would be the global evaluation factor (GEF). In addition, statistical analysis should be applied to determine whether there is a dose-related increase in MF. Such a procedure would disregard small increases in IMF, judged by experts in the assay to be of little or no toxicological significance, but would include statistical analysis to evaluate the presence of a positive dose-related trend.

The majority of the Workgroup members agreed that it would be desirable to use the multilaboratory distributions shown in Figure 1 to calculate the GEF for the agar and the microwell versions of the assay and that factor would be used for evaluating MLA experiments in all laboratories. After considerable discussion, the majority of the Workgroup members agreed that the GEF should be defined as the mean of the negative/solvent MF distribution plus one standard deviation. For the agar version of the assay the GEF would therefore be 90 and for the microwell version it would be 126 (see Fig. 1). The GEF would be applied as in the following example: If the negative/vehicle control MF in a microwell experiment is 50×10^{-6} , then one of the test cultures must have a MF of at least $50 + 126$ (the microwell GEF) $= 176 \times 10^{-6}$ to meet the GEF criterion for a positive call. An appropriate statistical trend test should be applied to determine whether there was a positive dose-related increase. This

approach should be applied both to experiments that utilize single cultures and those using duplicate, triplicate, etc. cultures for each data point. Of course, some statistical methods can only be used for experiments in which at least duplicate cultures are used.

A test agent response in an experiment is positive if *both* the IMF for any treatment meets or exceeds the GEF and a positive trend test is obtained. A test agent response is clearly negative if *both* the trend analysis and the GEF are negative. It is recognized that there will be experiments in which either (but not both) the GEF or the statistical analysis indicates a positive response. These situations should be evaluated on a case-by-case basis. It is generally advisable to conduct one or more additional experiments to better define the assay response (particularly in the (30–10)% RTG cytotoxicity range).

The majority of the Workgroup members feel that only those responses positive for both the GEF and the statistical trend analyses are biologically relevant. However, particular attention should be given to test agents, after rigorous testing, that are negative for the GEF, yet consistently show a positive trend test. It is possible that the test agent is very weakly mutagenic under the test conditions or contains a small amount of a mutagenic substance. These compounds may require further chemical characterization and, perhaps additional evaluation for mutagenic potential. The metabolism of these chemicals under the *in vitro* test conditions should be evaluated and the possibility considered that the *in vitro* metabolic conditions might be inadequate and that their *in vivo* metabolites might be mutagenic.

CURRENT WORKGROUP ACTIVITIES

To date, the Workgroup has completed its recommendations for two of the three issues identified during its meeting in Washington, DC. Currently, the Workgroup is beginning to address the issues related to the ICH recommendation for a 24-hr treatment in the absence of S9 metabolic activation. This recommendation has been in place long enough for laboratories to have substantial databases for the 24-hr treatment. Presently, the Workgroup is collecting data from which to base additional recommendations for this treatment condition.

REFERENCES

- Moore MM, Honma M, Clements J, Awogi T, Bolcsfoldi G, Cole J, Golapudi B, Harrington-Brock K, Mitchell A, Muster W, Myhr B, O'Donovan M, Ouldelhkim M-C, San R, Shimada H, Stankowski L, Jr. 2000. The mouse lymphoma thymidine kinase locus (Tk) gene mutation assay. In: International Workshop on Genotoxicity Test Procedures (IWGTP) Workgroup Report. *Environ Mol Mutagen* 35:185–190.

- Moore MM, Honma M, Clements J, Harrington-Brock K, Awogi T, Bolcsfoldi G, Cifone M, Collard C, Fellows M, Flanders K, Gollapudi B, Jenkinson P, Kirby P, Kirchner S, Kraycer J, McEnaney S, Muster W, Myhr B, O'Donovan M, Oliver J, Ouldelhkim M-C, Pant K, Preston R, Riach C, San R, Shimada H, Stankowski L, Jr. 2002. Mouse lymphoma thymidine kinase gene mutation assay. In: Follow-up International Workshop on Genotoxicity Test Procedures. New Orleans, Louisiana, April 2000. *Environ Mol Mutagen* 40:292-299.
- Moore MM, Honma M, Clements J, Bolcsfoldi G, Cifone M, Delongchamp R, Fellows M, Gollapudi B, Jenkinson P, Kirby P, Kirchner S, Muster W, Myhr B, O'Donovan M, Ouldelhkim M-C, Pant K, Preston R, Riach C, San R, Stankowski LF, Jr., Thakur A, Wakuri S, Yoshimura I. 2003. Mouse lymphoma thymidine kinase locus gene mutation assay. In: International Workshop (Plymouth, England) on Genotoxicity Test Procedures Workgroup Report. *Mutat Res* 540:127-140.
- In Vitro Mammalian Cell Mutation Test, OECD Guideline 476, adopted July 21, 1997.

Influence of SNPs in cytokine-related genes on the severity of food allergy and atopic eczema in children

Negoro T, Orihara K, Irahara T, Nishiyama H, Hagiwara K, Nishida R, Takagi H, Satoh K, Yamamoto Y, Shimizu S, Hagiwara T, Ishii M, Tanioka T, Nakano Y, Takeda K, Yoshimura I, Iikura Y, Tobe T. Influence of SNPs in cytokine-related genes on the severity of food allergy and atopic eczema in children.

Pediatr Allergy Immunol 2006 17: 583–590.

© 2006 The Authors

Journal compilation © 2006 Blackwell Munksgaard

Although many single nucleotide polymorphism (SNP) studies have reported an association of atopy, allergic diseases and total serum immunoglobulin E (IgE) levels, almost all of these studies sought risk factors for the onset of these allergic diseases. Furthermore, many studies have analyzed a single gene and hardly any have analyzed environmental factors. In these analyses, the results could be masked and the effects of other genes and environmental factors may be decreased. Here, we described the correlation between four genes [interleukin (IL)-4 (C-590T), IL-4 receptor (A1652G), FCER1B (G6842A) and STAT6 (G2964A)] in connection with IgE production; the role of IL-10 (C-627A) as a regulatory cytokine of allergy; and the severity of food allergy (FA) and atopic eczema (AE) in 220 Japanese allergic children. In addition to these SNPs, environmental factors, i.e., patient's attitude, indoor environment, and so on, were also investigated in this study.

Our study was retrospective, and the correlation was analyzed by our defined clinical scores divided into three terms: worst symptoms, recent symptoms and general amelioration at the most recent examination during the disease course. Our results indicated that IL-10 AA, the genotype with lower IL-10 production, is associated with higher IgE levels in the serum ($p < 0.0001$, estimate; 0.912). Marginal liver abnormalities were observed in the subject group with both FA and AE ($p < 0.1191$, estimate; 0.1490).

Our defined clinical scores enabled evaluation of various aspects of disease severity. Based on the scores, while no single SNP selected in this study determined severity, the combination of the SNP with laboratory data and environmental factors appeared to determine severity.

Takaharu Negoro¹, Kanami Orihara^{1,2,6}, Tomoko Irahara¹, Hiroshi Nishiyama³, Kanae Hagiwara¹, Risa Nishida^{2,6}, Hiroki Takagi³, Kazue Satoh¹, Yoshiki Yamamoto², Shunichi Shimizu⁴, Tamio Hagiwara⁵, Masakazu Ishii⁴, Toshihiro Tanioka¹, Yasuko Nakano¹, Ken Takeda⁶, Isao Yoshimura³, Yoji Iikura² and Takashi Tobe¹

¹Department of Medicinal Information, School of Pharmaceutical Sciences, Showa University, Hatanodai, Shinagawa-ku, Tokyo, Japan, ²Department of Paediatrics, School of Medicine, Showa University, Hatanodai, Shinagawa-ku, Tokyo, Japan, ³Department of Management Science, Faculty of Engineering, Tokyo University of Science, Kagurazaka, Shinjuku-ku, Tokyo, Japan, ⁴Department of Pathophysiology, School of Pharmaceutical Sciences, Showa University, Hatanodai, Shinagawa-ku, Tokyo, Japan, ⁵Department of Biochemistry, School of Medicine, Showa University, Hatanodai, Shinagawa-ku, Tokyo, Japan, ⁶Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Yamazaki, Noda-shi, Chiba, Japan

Key words: IL-10; FCER1B; STAT6; liver function; environmental factors; food allergy; atopic eczema

Takashi Tobe, Department of Medicinal Information, School of Pharmaceutical Sciences, Showa University, Shinagawa-ku, Tokyo 142-8555, Japan
Tel.: +81 03 3784 8031
Fax: +81 03 5749 7319
E-mail: ttobe@pharm.showa-u.ac.jp

Accepted: 10 July 2006

Atopy is a common familial trait characterized by increased specific or total serum immunoglobulin E (IgE) and underlies food allergy (FA) and atopic eczema (AE) among other childhood allergic diseases. As much as 95% of childhood allergy is associated with atopy and the cause of allergy involves both environmental and genetic risk factors. Genetic studies of atopic diseases

using genome screens and candidate gene approaches suggest that several genes have been implicated in the pathogenesis of the allergic diseases (1–6).

Although many genetic studies have analyzed single nucleotide polymorphisms (SNPs) as risk factors for allergic diseases (7–13), the aim of our research was to study the correlation between

SNPs of seven genes and the severity of FA and AE. Recently, the hygiene hypothesis focused on the prevention of atopy acquisition. In this theory, the surrounding environments during infancy play an important role in atopy predisposition for life (14, 15). Therefore, we used a questionnaire and clinical recordings to analyze the effect of environmental factors. Allergic pediatric subjects are mostly complicated by FA, AE, bronchial asthma (BA) and allergic rhinitis (AR). Therefore, we used the complicated subjects as the proper group for this study of genetic and environmental factors.

We focused on four candidate genes, interleukin-4 (IL-4), IL-4 receptor α -chain (IL-4R α), the β -subunit of the high-affinity IgE receptor (FCER1B) and signal transducer and activator of transcription 6 (STAT-6), for enhancement of IgE production and action (7–9, 16–18). Correlation with severity of allergic diseases was speculated to be much stronger with a combined analysis of a series of proteins for IgE production than single gene analysis. Furthermore, we also analyzed IL-10, which was reported as a regulatory cytokine that controls the balance between Th1/Th2 (19–21). Thus, low production of IL-10 appeared to lead to chronic inflammation at local sites (20). We selected these five SNPs (single SNP per one gene) to be functionally important on each gene and to be associated with atopy or allergy (18, 19, 21–26).

In the present study, we evaluated the disease severity of three aspects categorized by pharmacological medications and clinical manifestation and then correlated the categorized disease severity and the aforementioned seven genes. Thus, we revealed the masked effect of the other genes in the single gene analysis. We demonstrated that genetic and environmental factors played a part in exacerbations of atopic diseases.

Materials and methods

Subjects

Two hundred and twenty Japanese allergic subjects, who were regularly treated by only one doctor, were recruited for this study from our outpatient department. Thirty-three subjects were excluded from the study for various reasons and 19 nuclear families were included. The mean age of this group was 7.3 yr (range: 0–19 yr), with a median of 6.5 yr (s.d. = 4.5). The proportion of males to females in this group was about three to two. These subjects had complications of other allergic disorders, such as asthma, allergic rhinitis, and allergic conjuncti-

vitis other than AE and FA. Ethical approval was granted by the Showa University Medical and Pharmaceutical Ethics Committee Board, and written consent was obtained from all subjects and their parents. The clinical data extracted from clinical recordings were as follows: age, sex, family history, total serum IgE levels, eosinophil (%), IgE CAP RAST score, oral allergy syndrome symptoms (pruritus and angioedema of the lips, tongue and palate), blood biochemical parameters of liver function (GOT, GPT, LDH, and ALP), patient surrounding environmental conditions, and medications.

Classification of clinical data

The individual clinical data was gradually scored into five classes. We divided the family history, a risk factor of atopy, into five classes based on the number of family members with allergies as follows: 1: none; 2: one grandparent; 3: one parent; 4: a parent and a grandparent; and 5: both parents. In general, most children with AE have an allergic response to certain foods. Thus, the specific antibody or allergic response to food was detected in the allergic subjects with FA or AE. Positive responses to these foods (egg, milk, wheat, tree nuts, shellfish, peanuts, buckwheat, latex, and others) were expressed as the number of CAP RAST or oral allergy syndrome (OAS) symptoms. These responses were separated into five classes based on the presence of CAP RAST and OAS symptoms as follows: 1: none; 2: one or two; 3: three or four; 4: five or six; and 5: greater than seven. The GOT, GPT, LDH, and ALP data were used as an index of liver function. Evaluation of each value was based on Showa University Hospital's criteria. Liver function was divided into five classes based on the number of abnormal liver function tests as follows: 1: none; 2: one; 3: two; 4: three; 5: all. Total serum IgE (IU/mL) level was separated into five classes as follows: 1: below 100; 2: 100–500; 3: 500–1000; 4: 1000–5000; and 5: over 5000. The percentage of eosinophils (%) was divided into five classes as follows: 1: below 4; 2: 4–7; 3: 7–10; 4: 10–13; and 5: over 13. Mite RAST score was divided into five classes as follows: 1: zero; 2: one; 3: two or three; 4: four or five; and 5: six. Environmental conditions, including patient's attitude, indoor environment, cleaning, bathing, and discipline, of allergic subjects were extracted from clinical recordings and the questionnaire. As shown in Table 1, patient's attitude and indoor environment were assessed in five items, respectively. Conditions were separated into five classes based on the number of applicable criteria

Table 1. Primers and PCR conditions for PCR-RFLP.

Positions	Primer sequences	Primer	Restriction enzymes	Annealing temperature (°C)	PCR cycles	Mg ²⁺ (mM)	Size (bp)	
							Amplified fragment	Restricted fragment
IL-4 C-590T	5'-CACTAAACTTGGGAGAACATGGT-3'	F	<i>Ava</i> II	58	43	3.5	256	233, 23
	5'-TGCTTTGCATAGAAGGGA-3'	R						
IL-4R α 1652A/G Gln592Arg	5'-CCCCACCAAGTGGCTACC-3'	F	<i>Msp</i> I	58	43	1.5	105	89,16
	5'-GCCTTGTAACCAGCCTCTCCT-3'	R						
FCER1B 6842G/A Glu237Gly	5'-CAGGTTCCAGAGCATCGTG-3'	F	<i>Xmn</i> I	58	50	3.5	103	80,23
	5'-CTTATAAATCAATGGGAGGAAACA-3'	R						
IL-10 -627C/A	5'-GAAACATGTGCCTGAGAATCC-3'	F	<i>Rsa</i> I	58	43	3.5	198	126,72
	5'-TTAGGCAGTCACCTTAGGTCTC-3'	R						
STAT6 G/A	5'-GAAGTTCAGGCTCTGAGAGAC-3'	F	<i>Hga</i> I	58	50	2.5	215	194,21
	5'-GCCTCTAGTGTAAATGTGTCTG-3'	R						

F; Forward, R; Reverse, PCR; polymerase chain reaction, RFLP; restriction enzyme fragment length polymorphism.

as follows: 1: zero; 2: one of five; 3: two of five; 4: three of five; and 5: four of five. Cleaning and bathing were described as the number of times rooms were cleaned or the patient bathed a day. They were divided into three classes as follows: 1: over twice daily; 2: once daily; and 3: none daily. Discipline was expressed as exercises such as swimming that can reduce the amount of sweat on the skin, breathing relaxation techniques, or drinking cold water for management of autonomic nerve balance. This was separated into three classes as follows: 1: daily; 2; every few days; and 3: rarely.

Classification of medication

Disease severity was evaluated in three frames. The worst symptoms were designated a score based on the drugs or diets used at the worst stage of disease. Recent symptoms were designated a score based on the drugs or diets in current use. The worst or recent symptoms of AE were evaluated by the prescribed drugs based on Japanese AE guidelines. FA symptoms were evaluated by the extent of allergen elimination in diets based on Japanese FA guidelines. Symptoms were separated into five classes as follows: 1: none; 2: mild; 3: moderate; 4: severe; and 5: most severe. General amelioration of FA and AE was represented by a score based on the change in symptoms of allergic subjects from the previous to the latest examination. This was evaluated by clinical records and the questionnaire. While this characteristic is based on subjective subjects, this was felt to be appropriate for the study as only one doctor performed the evaluations. Amelioration was divided into five classes as follows: 1: no treatment required; 2: very good improvement; 3: good improvement; 4: slight improvement; 5: poor control.

Genotyping of SNPs

DNA samples were extracted from whole peripheral blood with the Wizard Genomic DNA Purification Kit (Promega, WI, USA) and were genotyped for SNPs by polymerase chain reaction-restriction enzyme fragment length polymorphism (PCR-RFLP).

The region surrounding the polymorphisms was amplified by PCR using the conditions listed in Table 1. PCR was carried out in a volume of 50 μ L containing 100 ng of DNA and 0.5 μ mol/L of each primer. The PCR of FCER1B and STAT6 were performed using the hot-start method with 1 U of KOD-DNA polymerase (TOYOBO, Osaka, Japan). The parameters for thermocycling were as follows: denaturation at 95°C for 5 min, followed by 50 cycles of denaturation at 94°C for 15 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s. This was followed by a final extension at 72°C for 6 min. The amplifications of IL-4, IL-4R, and IL-10 genes were performed with 1 U of EX Taq-DNA polymerase (TAKARA, Osaka, Japan). The conditions for amplification of these genes were as follows: denaturation at 95°C for 5 min, followed by 43 cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s. This was followed by a final extension at 72°C for 6 min.

Identification of the SNPs in PCR products was performed by incubation with a restriction enzyme chosen to cut one of the two alleles (Table 1), followed by electrophoresis on 2% agarose gels or 8% polyacrylamide gels (Fig. 1).

Statistical analysis

This study was necessary to determine of the extent to which the severity of atopic diseases are




Fig. 1. Polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP)-based genotyping of cytokine gene polymorphisms. Seven allergy-specific genes were analyzed with the PCR–RFLP method. Restricted or non-restricted PCR products with specific enzymes were loaded on 2% agarose gel or 8% polyacrylamide gel and stained with ethidium bromide (see Table 1).

based on the host and environmental factors. For comparisons of factors divided into two groups based on a yes/no response, chi-square analysis was used. First, all interactions were considered under a value of $p < 0.2$. Second, we listed all interactions to be biologically considered. The evaluations of the worst symptoms, recent symptoms, and general amelioration of each allergic disease were used as response variables, and all laboratory data, SNPs, and interactions in the study were used as explanatory variables. The p value was estimated using simple regression analysis.

All testing was done using a JMP program (SAS Institute, Cary, NC, USA) for Windows computers, developed from the SAS-based system.

Results

Genotype frequencies

A total of 220 DNA samples from the Japanese children were amplified by PCR in order to genotype the polymorphisms of the four cytokines, two receptors, and one transcription factor genes. The bi-allelic polymorphisms were coded into three classes and the genotype distribution was assessed. The allele frequencies are shown in Table 2. The IL-10*-627A allele was major and the C allele was minor. Similarly, the IL-4*-590T and IL-4R α *1652A alleles were major.

Influence of genetic and environmental factors on disease severity

Table 3 showed that the AA genotype, with low production of IL-10, was inadequate to regulate the IgE level ($p = 0.0001$). The subpopulation with both an IL-4 CT and STAT6 AG genotype

easily elevated IgE ($p = 0.003$). Similarly, the subpopulation with both the IL-4R AA and STAT6 AG genotype was strongly correlated with the eosinophil percentage. This suggested that these subpopulations easily increased the aforementioned laboratory data. Naturally, the serum IgE level, the eosinophil percentage, and the mite-specific IgE score were strongly correlated with each other. As environmental factors, discipline and bathing were good actions for ameliorating IgE levels or mite-specific IgE scores, respectively.

Influence of genetic and environmental factors on disease severity of FA (Table 4)

FA refers to an adverse immunologic response to proteins in food. In the food allergic reaction, there are both IgE-mediated and non-IgE-mediated gastrointestinal reactions. Infant FA generally associates with atopic diseases (i.e.,

Table 2. Genotype frequencies

Genes	No. of cases	Genotypes					
		TT		CT		CC	
IL-4	186	99	53%	79	42%	8	4%
		GG		AG		AA	
IL-4R α	177	3	2%	53	30%	121	68%
		GG		AG		AA	
FCER1B	185	10	5%	77	42%	98	53%
		AA		AC		CC	
IL-10	185	73	39%	93	50%	19	10%
		GG		AG		AA	
STAT6	173	16	9%	72	42%	85	49%

Table 3. Simple linear regression analysis of Laboratory Data

Factor	IgE			Mite			Eosinophile			Positive Food		
	P value	Estimate	Genotype	P value	Estimate	Genotype	P value	Estimate	Genotype	P value	Estimate	Genotype
IL-4R										0.0200*	0.5200	AG
IL-10	0.0001***	0.9120	AA									
STAT6	0.0102*	0.6350	G allele									
IL-4R*STAT6							0.0179*	0.8030	AA-AG			
IL-4*STAT6	0.0030*	0.9160	CT-AG									
IgE				0.0001***	0.7910		0.0001***	0.5970				
Mite	0.0001***	0.6300										
Eosinophile	0.0001***	0.4780										
Bathing Discipline				0.0685	-0.5490							
Discipline	0.0448*	-0.4790										

*p < 0.05, **p < 0.01, ***p < 0.001.

Table 4. Simple linear regression analysis of Food Allergy

Factors	Genotypes or groups	Worst symptoms		Recent symptoms		General amelioration	
		P value	Estimate	P value	Estimate	P value	Estimate
Age	Matured					0.0354*	0.0127
FCER1B	AA			0.0135*	0.3750		
Food-specific IgE	Many	0.0709	0.2172	0.0001***	0.4760	0.0873	0.1856
FCER1B* Liver Function	AA* Bad	0.2438	0.1673	0.0137*	0.3750		
Eosinophile* Discipline	High* Well					0.0765	-0.7705
IgE* Discipline	High* Well					0.2193	-0.2759

*p < 0.05, **p < 0.01, ***p < 0.001.

atopic eczema and asthma). In this study, 93% of total FA subjects also had atopic eczema (Fig. 2). Therefore, the finding that the number of food-specific IgE antibodies in pediatric FA subjects was correlated with the severity of disease is consistent with this general opinion (Worst symptoms: p = 0.0709; recent symptoms: p = 0.0001; general amelioration: p = 0.0873). FA symptoms are usually ameliorated with maturation but are

difficult to ameliorate when teenagers experience FA (general amelioration: p = 0.0354).

Interestingly, the FCER1B 6842AA genotype was correlated with significantly more severe FA than the other genotypes (recent symptoms: p = 0.0135). Furthermore, the combination of FCER1B 6842AA and abnormalities of liver function were more related to disease severity than any single factor (recent symptoms: p = 0.0137). However, previous reports indicated that the G genotype transmitted much stronger cellular signaling than the A genotype and was associated with childhood atopic asthma. It is speculated that the weak signal was appropriate for FA and chronic marginal inflammation of the liver gradually disturbed oral tolerance.

In specific subpopulations with high levels of eosinophils or IgE, discipline had a positive effect on general amelioration (p = 0.0765 and p = 0.2193, respectively).




Fig. 2. Ratio of complications between food allergy (FA) and atopic eczema (AE). AE was a complication in 93% of food allergic subjects. FA complicated 49% of AE subjects. The frequency of food allergic subjects with AE was very high.

Influence of genetic and environmental factors on disease severity of AE (Table 5)

AE is a chronic inflammatory skin disease that is considered familial with allergic features. It often

Table 5. Simple linear regression analysis of Atopic Eczema

Factors	Genotypes or groups	Worst symptoms		Recent symptoms		EGeneral amelioration	
		P value	Estimate	P value	Estimate	P value	Estimate
IL-10	AA	0.0153*	0.3485	0.0148*	0.5549	0.0439*	0.3765
Food-specific IgE	Many	0.0607	0.2911			0.1506	0.2924
IgE	High	0.0004***	0.5018	0.0001***	1.1458	0.0004***	0.6501
STAT6* Eosinophile	A allele* High	0.0615	0.3020	0.0011**	0.8344	0.0001***	0.8876
IL-10* Liver Finction	AA* Bad	0.2376	0.1308	0.0092**	0.8328	0.0048**	0.7563
Mite* Cleaning	High* Bad			0.1296	0.5619	0.0905	0.5103

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

occurs in patients with other atopic disorders, such as asthma and allergic rhinitis. Figure 2 showed that almost 50% of patients with AE also had allergic rhinitis. Consistent with general opinions, a high level of serum IgE was significantly related to the severity of AE (worst symptoms: $p = 0.0004$; recent symptoms: $p = 0.0001$; general amelioration: $p = 0.0004$). A combination of the IL-10 AA genotype and abnormalities of liver function was much more correlated with disease severity than the IL-10 AA genotype alone. Thus, low producers of IL-10 could not regulate IgE production but did have exacerbations of AE symptoms. In this specific population, marginal inflammation in the liver affected atopic skin disease. The children with hyperreactivity to food allergens also had severe AE. In the specific subpopulation with a high level of mite-specific IgE, AE symptoms were influenced by indoor surroundings. Interestingly, the STAT6 A genotype seemed to be linked with eosinophilia in local inflammatory sites, especially in the specific subpopulation with high levels of eosinophils in the blood.

Discussion


Atopy is a heterogeneous disease determined by genetic and environmental interactions. The genetic contribution to atopic allergy was calculated to vary between 36 and 79% in twin studies (27–29). We investigated the correlation of disease severity of FA or AE with SNPs in seven genes previously identified to be putative atopy genes by linkage and association studies. In addition to single SNP analysis, the combination of the SNP analysis, laboratory data, and environmental factors were analyzed in this study.

In our study, a couple of SNPs were observed to be correlated with increased severity of FA and AE in Japanese children. IL-10, which is produced by Th₂ and T regulatory 1 (Tr₁) cells, was initially identified in mice as the inhibitory

factor of antigen-specific Th₁ cell proliferation and production of IFN- γ (30). IL-10 is a very important molecule as it inhibits many functions of immunocytes as a negative feedback regulator. Rosenwasser et al. (20) reported that the A/A genotype of the IL-10 -627C/A promoter polymorphism diminished promoter strength more than the C/C genotype. They speculated that persistent inflammation leads to prolonged and severe asthma episodes owing to lower IL-10 levels. Consistent with this report, our data indicated that lower production of IL-10, as in the AA genotype, was significantly correlated with severity of AE. It was observed that these genotypic subjects tended to produce high levels of IgE, which is typically associated with severity of AE.

Moreover, Iikura et al. (31) reported that the serum transaminase level was often slightly increased in infants who suffered from food-induced AE. The liver plays an important role in induction of oral tolerance. Liver B220⁺ DC have the ability to induce apoptosis of activated T cells and generate immune regulatory activity by promoting Tr₁ cell differentiation (32). In addition, marginal liver damage caused impairment of DC activity following Tr₁ cell differentiation. The Tr₁ cell exhibits regulatory function following IL-10 production. Thus, it was speculated that the IL-10 AA genotype with marginal liver inflammation easily exacerbated FA and AE symptoms as a result of disruption of oral tolerance. Surprisingly, the IL-10 A/A genotype was more correlated with disease severity in subjects with both FA and AE than the other genotypes (Fig. 3). However, as serum total IgE level was not correlated with severity of FA, the regulatory mechanisms of FA and AE might differ. Therefore, in the specific subgroup with both illnesses, the IL-10 SNP was related to severity of illness. These data indicated that IL-10-sensitive and insensitive groups may exist among the FA subjects.

Fig. 3. The correlation between total serum IgE levels and the promoter polymorphism of the IL-10 gene. Total serum IgE levels were higher in allergic subjects with the IL-10 promoter -627 AA genotype than the other genotype. The IL-10 AA genotype was 3.35 ± 0.18 (mean \pm s.e.). The other genotype was 2.43 ± 0.15 .



The number of food-specific IgE was significantly related to the severity of FA and AE. Thus, several food antigens may be responsible for the slight impairment of the system of oral tolerance. The FCER1B 6842A/G (E237G) polymorphism is adjacent to an immunoreceptor tyrosine-based activator motif (ITAM) site, which interacts with γ chains and influences the efficiency of IgE cell signaling involving *lyn* and *src* (33). The 6842 A/G SNP was tightly linked with the -426 T/C and -654 C/T SNPs, which were responsible for the association with atopy (34). These promoter SNPs enhanced the transcriptional activity and increased the expression of FCER1B in blood basophils. However, in the present data, the genotype with lower transcriptional activity and abnormal liver function had more severe FA. This may be because of the effect of other promoter SNPs of FCER1B on FA. Second, while marginal liver damage existed in patients, lower expression levels of FCER1B in basophils and mast cells might play an important role in FA.

Shirakawa et al. (8) reported that the G allele was present in 10% of Japanese atopic asthma children. They also noted that genetic effects of FCER1B were much more prominent in childhood asthma. The proportion of the 6842A/G polymorphism in the study was quite different from our data, in which the G allele was present in 23.5% of the Japanese pediatric population. The difference may be explained by the possibility that genetics facilitated exacerbations in our population, e.g., comprised of various allergic diseases such as FA, AE, and asthma.

Furthermore, environmental factors may significantly affect the severity of FA and AE in specific subpopulations. Well-performed bathing and discipline improved high levels of serum total IgE and mite-specific IgE. Naturally, this

suggested that the effect of SNPs was masked by these factors in these specific subpopulations, i.e., the high level of serum IgE group. However, strict adherence to disciplines improved only the general amelioration of FA in groups with high levels of eosinophils or total serum IgE. These results indicated that more subjective evaluations might be represented in the diagnosis. For this reason, we also adopted medication and laboratory data for objective evaluation.

As the number of subjects was small and most subjects had complications, we did not have large statistical power. Therefore, the interactions of only two factors could be analyzed with a sufficient p value and estimate. In addition, we could not study non-allergic control children for ethical reasons. As we did not research all SNPs per one gene, we could not suggest whether other single SNP not analyzed in this study was associated with severity of FA and AE in Japanese children. However, the present study provides useful preliminary data.

Our data presented the laboratory data of liver function and SNPs, especially IL-10 and FCER1B, which might serve in the evaluation of disease severity. Moreover, our results indicated that these genetic polymorphisms may be correlated with risk factors not only for the onset but also for the severity of allergy. The combination of environmental factors and SNP analysis easily detected specific subpopulations. We believe that this kind of analysis is useful for research on the correlation of disease severity and SNPs.

References

1. COOKSON WO, SHARP PA, FAUX JA, HOPKIN JM. Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome 11q. *Lancet* 1989; 1: 1292-5.

2. DANIELS S, BHATTACHARRYA S, JAMES A, et al. A genome-wide search for quantitative trait loci underlying asthma. *Nature* 1996; 383: 247–50.
3. LAITINEN T, DALY MJ, RIOUX JD, et al. A susceptibility locus for asthma-related traits on chromosome 7 revealed by genome-wide scan in a founder population. *Nature Genet* 2001; 28: 87–91.
4. HAAGERUP A, BJERKE T, SCHIOTZ PO, BINDERUP HG, DAHL R, KRUSE TA. Asthma and atopy – a total genome scan for susceptibility genes. *Allergy* 2002; 57: 680–6.
5. COOKSON WO, YOUNG RP, SANDFORD AJ, et al. Maternal inheritance of atopic IgE responsiveness on chromosome 11q. *Lancet* 1992; 340: 381–4.
6. MOATT MF, SHARP PA, FAUX JA, YOUNG RP, COOKSON WO, HOPKIN JM. Factors confounding genetic linkage between atopy and chromosome 11q. *Clin Exp Allergy* 1992; 22: 1046–51.
7. SHIRAKAWA T, DEICHMANN KA, IZUHARA K, MAO I, ADRA CN, HOPKIN JM. Asthma, atopy and genetic variants of IL-4 and IL-13 signalling. *Immunol Today* 2000; 21: 60–4.
8. SHIRAKAWA T, LI A, DUBOWITZ M, et al. Association between atopy and variants of the subunit of high affinity immunoglobulin E receptor. *Nature Genet* 1994; 7: 125–30.
9. HOOK S, CHENG P, HOLLOWAY J, et al. Analysis of two IL-4 promoter polymorphisms in a cohort of atopic and asthmatic subjects. *Exp Clin Immunogenet* 1999; 16: 33–5.
10. MORAHAN G, HUANG D, WU M, et al. Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children. *Lancet* 2002; 360: 455–9.
11. TANAKA H, MIYAZAKI N, OASHI K, et al. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. *J Allergy Clin Immunol* 2001; 107: 331–6.
12. ARBOUR NC, LORENZ E, SCHUTTE BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nature Genet* 2000; 25: 187–91.
13. VAN EERDEWEGH P, LITTLE RD, DUPUIS J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. *Nature* 2002; 418: 426–30.
14. ROMAGNANI S: Immunologic influences on allergy and the TH1/TH2 balance. *J Allergy Clin Immunol* 2004; 113: 395–400.
15. LIU AH. Endotoxin exposure in allergy and asthma: reconciling a paradox. *J Allergy Clin Immunol* 2002; 109: 379–92.
16. HERSHEY GK, FRIEDRICH MF, ESSWEIN LA, THOMAS ML, CHATILA TA. The association of atopy with a gain-of-function mutation in the α subunit of the interleukin-4 receptor. *N Engl J Med* 1997; 337: 1720–5.
17. HEINZMANN A, MAO X-Q, AKAIWA M, et al. Genetic variants of IL-13 signalling and human asthma and atopy. *Hum Mol Genet* 2000; 9: 549–59.
18. GAO P-S, MAO X-Q, ROBERTS MH, et al. Variants of STAT6 (signal transducer and activator of transcription) in atopic asthma. *J Med Genet* 2000; 37: 380–2.
19. HOBBS K, NEGRI J, KLINNERT M, ROSENWASSER LJ, BORISH L. Interleukin-10 and transforming growth factor- β promoter polymorphisms in allergies and asthma. *Am J Respir Crit Care Med* 1998; 158: 1958–62.
20. ROSENWASSER LJ, BORISH L. Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). *Am J Respir Crit Care Med* 1997; 156: S152–5.
21. LECH-MARANDA E, BASEGGIO L, BIENVENU J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. *Blood* 2004; 103: 3529–34.
22. WALLEY AJ, COOKSON WO. Investigation of an interleukin-4 promoter polymorphism for association with asthma and atopy. *J Med Genet* 1996; 33: 689–92.
23. NOGUCHI E, SHIBASAKI M, ARINAMI T, et al. Association of asthma and the interleukin-4 promoter gene on Japanese. *Clin Exp Allergy* 1998; 28: 449–53.
24. RISMA KA, WANG N, ANDREWS RP, et al. V75R576 IL-4 receptor alpha is associated with allergic asthma and enhanced IL-4 receptor function. *J Immunol* 2002; 169: 1604–10.
25. WOITSCH B, CARR D, STACHEL D, et al. A comprehensive analysis of interleukin-4 receptor polymorphisms and their association with atopy and IgE regulation in childhood. *Int Arch Allergy Immunol* 2004; 135: 319–24.
26. NISHIYAMA C, AKIZAWA Y, NISHIYAMA M, et al. Polymorphisms in the Fc epsilon RI beta promoter region affecting transcription activity: a possible promoter-dependent mechanism for association between Fc epsilon RI beta and atopy. *J Immunol* 2004; 173: 6458–64.
27. HOPP RJ, BEWTRA AK, WATT GD, NAIR NM, TOWNLEY RG. Genetic analysis of allergic disease in twins. *J Allergy Clin Immunol* 1984; 73: 265–70.
28. DUFFY DL, MARTIN NG, BATTISTUTTA D, HOPPER JL, MATHEWS JD. Genetics of asthma and hay fever in Australian twins. *Am Rev Respir Dis* 1990; 142: 1351–8.
29. NIEMINEN MM, KAPRIO J, KOSKENVUO M. A population-based study of bronchial asthma in adult twin pairs. *Chest* 1991; 100: 70–5.
30. FIORENTINO DF, BOND MW, MOSMANN TR. Two types of mouse T helper cell: Th₂ clones secrete a factor that inhibits cytokine production by Th₁ clones. *J Exp Med* 1989; 170: 2081–95.
31. IIKURA Y, IWASAKI A, TSUBAKI T, et al. Study of liver function in infants with atopic dermatitis using the ¹³C-methacetin breath test. *Int Arch Allergy Immunol* 1995; 107: 189–93.
32. QIAN S, LU L. Mechanisms of hepatic tolerance. In: GERCHWIN ME, VIERLING JM, MANNS MP, eds. *Liver Immunology*. Philadelphia: HANLEY & BELFUS, INC, 2003: 115–28.
33. THOMAS NS, WILKINSON J, HOLGATE ST. The candidate region approach to the genetics of asthma and allergy. *Am J Respir Crit Care Med* 1997; 156: S144–51.
34. NISHIYAMA C, AKIZAWA Y, NISHIYAMA M, et al. Polymorphisms in the Fc ϵ R1 β promoter region affecting transcription activity: a possible promoter-dependent mechanism for association between Fc ϵ R1 β and Atopy. *J Immunol* 2004; 173: 6458–64.

医薬統計の原理・原則

吉村 功
東京理科大学

1. 動機

学術雑誌に自分の研究結果を掲載してもらおうとする研究者は、論文原稿をその雑誌に投稿して審査を受ける。雑誌の編集責任者は、あるレベル以上と思われる関連分野の専門家にその審査を依頼する。依頼された専門家（査読者）は、(1) 採択が妥当である、(2) 棄却が妥当である、(3) 適切な改訂が行われれば採択が妥当である、という三つの選択肢の一つを選ぶ。

(3) を選んだ場合査読者は、必要な改訂の指示・指摘を査読結果として提出する。編集責任者は論文原稿の著者にこの指示・指摘を伝える。著者は指示・指摘が妥当であれば改訂を行い、妥当でなければ反論を行う。編集責任者はその改訂・反論の妥当性を査読者と共に検討し、最終的な採択・棄却の判断を下す。これが学術雑誌の通常のやり方である。

私は数人の共同研究者と共著で、ある雑誌に「複数の主要評価変数を想定した臨床試験における被験者数設定法」についての論文原稿を投稿した。この投稿に対して、しばらく経ってから、「... 相間の正確な見積りは難しいと考えられます。だとすればよく行われているように相間 0 の前提下に症例数を見積もるのが、一般に安全で賢明なやりかただと考えられます。」という指摘が編集責任者から送られてきた。われわれの研究によると、相関を 0 にすると、そうでない場合に比べて被験者数が多くなる。従ってこの指摘は「被験者は多めに評価するのが安全で賢明」と述べていることになる。

われわれは、この指摘を、被験者数設定の原理・原則に反するものと考え、反論を行った。結果としてそれは受け入れられたが、査読者というものは、それなりのレベルの専門家である。それが原理的に妥当でない判断を出してくるのには、背景に、この考え方を当然とする多くの人がいることを意味している。だとすれば単に個別に反論するのではなく、公の場で一般論として、原理・原則を確認する機会を用意した方が良いのではなかろうか。これが今回、この課題を設定した動機である。原理・原則というものは、それをお互いが納得した上で、実用上の柔軟性をどのように取り入れるかを考えるべきだと思うからである。

2. 想定する状況と用語法

短い時間で実りある議論をしたいので、ここでは話題・課題をある程度限定する。用いる用語もそれに合わせて限定することにする。私が近年関係している分野は医薬統計なので、課題を医薬統計に設定する。主たる対象は医薬品であるが、毒性試験等では化粧品や環境汚染物質などにも言及する。

医薬品についての一般原則は、「薬としての価値がある物は可能な限り早く、安い費用で、患者と医師の手元に届け、薬としての価値がない物は患者と医師が使わない状況を作る」ことである。化粧品や環境汚染物質などについての一般原則は、危険と利得のバランスという視点ではなく、「社会的に受け入れられる水準を超える危険性を持つものは規制する」ことである。

統計学ではサンプルサイズと言われているものが、医薬統計では慣用的に「症例数」（ヒトの場合）、「動物数」「例数」（動物の場合）、「n 数」（インビトロ試験等）と言われている。本稿では、ヒトが対象のときに「被験者数」、動物個体が対象のときに「動物数」、インビトロ試験での繰り返し数の類のものを「サンプルサイズ」と言うことにする。

薬事法では、「薬」という用語をかなり限定したものとして使っている。それをそのまま使うと、開発中の薬の候補物には薬という用語が使えない。それは不便なので、ここでは「被験薬」「被験物」「薬物」という用語を慣例に合わせて使う。

以上の前提の下では、薬効も毒性も、複数の区分での評価変数・反応の比較という形で評価がなされる。この区分を「群」と言うことにする。群がある被験物・薬のある用量と対応している試験を「用量群試験」と言うことにする。

3. 臨床試験と非臨床試験

医薬統計では、臨床試験と非臨床試験には大きな状況の違いがある。ヒトと非ヒトとの間の倫理面での重要度の違いと、被験者・物の個体差・個人性の認識の仕方の違いである。

倫理面について言うと、臨床試験も非臨床試験も、実質は実験であるから、実験台として生体に損害・ダメージが生じる可能性が存在する。その損害が致命的な場合、対象がヒトであれば申し訳ないと頭を下げるだけで済まないが、動物であればやむを得ないとして済みますことになる。倫理面の重要性に質的な差があるというのは社会の共通了解であろう。